Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Digestive Diseases and Sciences
Erschienen in: Digestive Diseases and Sciences 7/2012

01.07.2012 | Review

Clinical Perspective: Statins and the Liver—Harmful or Helpful?

verfasst von: James H. Lewis

Erschienen in: Digestive Diseases and Sciences | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Excerpt

The safety of 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase inhibitors (statins) remains very much in the news, with recent regulatory alerts issued about the potential for effects on memory loss, an increased risk of type 2 diabetes, myopathy, and possible drug interactions involving HIV and hepatitis C protease inhibitors [1‐3]. Although the US Food and Drug Administration (FDA) currently considers serious statin-related liver injury to be a rare and unpredictable event [1], it nevertheless remains an important concern among physicians and patients alike. Moreover, the risk of adverse hepatic events receives renewed emphasis with each new case series that appears in the literature. Indeed, the proportion of patients who are not being prescribed statins because of the potential for adverse hepatic events, but who might otherwise benefit from their cardioprotective effects, is substantial [4]. …
Literatur
1.
2.
3.
4.
Rzouq FS, Volk ML, Hatoum HH, et al. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am J Med Sci. 2010;340:89–93.PubMedCrossRef
5.
Bergmann OM, Kristjansson G, Jonasson JG, Bjornsson ES. Jaundice due to suspected statin hepatotoxicity: a case series. Dig Dis Sci. (Epub ahead of print). doi: 10.​1007/​s10620-011-1950-1.
6.
Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56:374–380.PubMedCrossRef
7.
8.
Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have a higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci. 2005;329:62–65.PubMedCrossRef
9.
Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology. 2008;48:662–669.PubMedCrossRef
10.
Onusko E. Statins and elevated liver tests: what’s the fuss? J Fam Pract. 2008;57:449–452.PubMed
11.
12.
13.
14.
Cohen DE, Anania FA, Chalasani N, The National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97:S77–S81.
15.
Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis. 2009;29:412–422.PubMedCrossRef
16.
Athyros VG, Tziomalos K, Gossios T, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests; in the Greek atorvastatin and coronary heart disease evaluation (GREACE) study: a post hoc analysis. Lancet. 2010;376:1916–1922.PubMedCrossRef
17.
18.
Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007;46:1453–1563.PubMedCrossRef
19.
Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc. 2010;85:349–356.PubMedCrossRef
20.
Tandra S, Vuppalanchi R. Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med. 2009;11:272–278.PubMedCrossRef
21.
Tzefos M, Olin JL. 3-hydroxyl-3-methylglutaryl coenzyme a reductase inhibitor use in chronic liver disease: a therapeutic controversy. J Clin Lipidol. 2011;5:450–459.PubMedCrossRef
22.
Tolman K. Defining patient risks from expanded preventive therapies. Am J Cardiol. 2000;85:15E–19E.PubMedCrossRef
23.
Avins AL, Manos MM, Ackerson L, et al. Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study. Drug Saf. 2008;31:325–334.PubMedCrossRef
24.
Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology. 2005;41:690–695.PubMedCrossRef
25.
Björnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol. 2005;40:1095–1101.PubMedCrossRef
26.
Björnsson E, Olsson R. Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis. 2006;38:33–38.PubMedCrossRef
27.
Kornbrust DJ, MacDonald JS, Peter CP, et al. Toxicity of the HMG-CoA reductase inhibitor, lovastatin, to rabbits. J Pharmacol Exp Ther. 1989;248:498–505.PubMed
28.
Horsmans Y, DeSager JP, Harveng TC. Biochemical changes and morphological alterations of the liver in guinea pigs after administration of simvastatin HMG-CoA reductase-inhibitor. Pharmacol Toxicol. 1990;67:336–339.PubMedCrossRef
29.
Zimmerman HJ. The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999:662.
30.
Tavintharan S, Ong CN, Jeyaseelan K, et al. Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: a possible role in statin-induced hepatotoxicity? Toxicol Appl Pharmacol. 2007;223:173–179.PubMedCrossRef
31.
Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49:2231–2237.PubMedCrossRef
32.
33.
Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114:2788–2797.PubMedCrossRef
34.
de Denus S, Spinler SA, Miller K, et al. Statins and liver toxicity: a meta-analysis. Pharmacotherapy. 2004;24:584–591.PubMedCrossRef
35.
Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective pravastatin pooling (PPP) project. Circulation. 2002;105:2341–2346.PubMedCrossRef
36.
Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615–1622.PubMedCrossRef
37.
Charles EC, Olson KL, Sandhoff BG, et al. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med. 2005;118:618–624.PubMedCrossRef
38.
Mindikoglu AL, Magder LS, Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing Database. Liver Transpl. 2009;15:719–729.PubMedCrossRef
39.
Reuben A, Koch DG, Lee WM, The Acute Liver Failure Study Group. Drug-induced acute liver failure: results of an US Multicenter, prospective study. Hepatology. 2010;52:2065–2076.
40.
Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512–521.PubMed
41.
Björnsson E, Olsson R. Outcome and prognostic markers in sever drug-induced liver disease. Hepatology. 2005;42:481–489.PubMedCrossRef
42.
Devarbhavi H, Dierkhising R, Kremers WK, et al. Single center experience with drug-induced liver injury from India: Causes, outcomes, prognosis, and predictors of mortality. Am J Gastroenterol. 2010;105:2396–2404.PubMedCrossRef
43.
Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135:1924–1934.PubMedCrossRef
44.
Weber JCP. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. In: Rainsford KD, Velo GP, eds. Advances in inflammation research, vol. 6. New York: Raven Press; 1984:1–7.
45.
Davern TJ, Chalasani N, Fontana RJ, et al. Acute Hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141:1665–1672.PubMedCrossRef
46.
Dalton HR, Fellows HJ, Stableforth W, et al. The role of hepatitis E testing in drug-induced liver injury. Aliment Pharmacol Ther. 2007;26:1429–1435.PubMedCrossRef
47.
Lewis JH. Drug-induced liver disease. Med Clin North Am. 2000;84:1275–1311.
48.
Lewis JH. Liver disease caused by anesthetics, toxins, and herbal preparations. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger & Fordtran’s Gastrointestinal and Liver Diseases. Pathophysiology/Diagnosis/Management. 9th edition. 2010;1447–1476.
49.
Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323–1330.PubMedCrossRef
50.
Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46:1331–1336.PubMedCrossRef
51.
Agarwal VK, McHutchison JG, Hoofnagle JH. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol. 2010;8:463–470.PubMedCrossRef
52.
Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54:931–939.PubMedCrossRef
53.
Lewis JH. Liver biopsy differentiates DILI from autoimmune hepatitis. Nature Rev Gastroenterol Hepatol. 2011;8:540–542.CrossRef
54.
Lewis JH, Kleiner D. Hepatic Injury due to Drugs, herbal compounds, chemicals and toxins. In: Burt AD, Portmann BC, Ferrell LD, eds. MacSween’s Pathology of the Liver. 6th ed. Edinburgh: Churchill Livingstone Elsevier; 2012:645–760.CrossRef
55.
Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: Promises and pitfalls. Clin Liver Dis. 2007;11:477–505.PubMedCrossRef
56.
Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51:2117–2126.PubMedCrossRef
57.
Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ. 1999;319:1541.PubMedCrossRef
58.
Björnsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther. 2010;32:3–13.PubMed
59.
Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology. 2001;33:308–310.PubMedCrossRef
60.
Nathwani RA, Kumar SR, Reynolds TB, et al. Marked elevation in serum transaminases: an atypical presentation of choledocholithiasis. Am J Gastroenterol. 2005;100:295–298.PubMedCrossRef
61.
Henrion J, Schapira M, Luwaert R, et al. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore). 2003;82:392–406.CrossRef
62.
Lee WM, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf. 2005;28:351–370.PubMedCrossRef
63.
Lewis JH, Larrey D, Olsson R, et al. Utility of the Roussel Uclaf causality assessment method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran. Int J Clin Pharmacol Ther. 2008;46:327–339.PubMed
64.
Friis RH, Sellers TA. Epidemiology for Public Health Practice. Sudbury, MA: Jones & Bartlett Learning 2009:93–140.
65.
Berry DC, Knapp P, Raynor DK. Provision of information about drug side-effects to patients. Lancet. 2002;359:853–854.PubMedCrossRef
66.
Khorashadi S, Hasson NK, Cheung RC. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol. 2006;4:902–907.PubMedCrossRef
67.
Segarra-Newnham M, Parra D, Martin-Cooper EM. Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus. Pharmacotherapy. 2007;27:845–851.PubMedCrossRef
68.
Henderson LM, Patel S, Giordano TP, Green L, El-Serag HB. Statin therapy and serum transaminases among a cohort of HCV-infected veterans. Dig Dis Sci. 2010;55:190–195.PubMedCrossRef
69.
Madhoun MF, Bader T. Statins improve ALT values in chronic hepatitis C patients with abnormal values. Dig Dis Sci. 2010;55:870–871.PubMedCrossRef
70.
Harrison SA, Rossaro L, Hu KQ, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology. 2010;52:864–874.PubMedCrossRef
71.
Gopal K, Johnson TC, Gopal S, et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology. 2006;44:335–340.PubMedCrossRef
72.
Molina S, Castet V, Fournier-Wirth C, et al. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol. 2007;46:411–419.PubMedCrossRef
73.
Amemiya F, Maekawa S, Itakura Y, et al. Tageting lipid metabolism in the treatment of hepatitis C virus infection. J Infect Dis. 2008;197:361–370.PubMedCrossRef
74.
Ikeda M, Abe K, Yamada M, et al. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology. 2006;44:117–125.PubMedCrossRef
75.
Ikeda M, Kato N. Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon. J Pharmacol Sci. 2007;105:145–150.PubMedCrossRef
76.
Delang L, Paeshuvse J, Vliegen I, et al. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatolohy. 2009;50:6–16.CrossRef
77.
Mihaila R, Nedelcu L, Fratila O, et al. Lovastatin and fluvastatin reduce viremia and the pro-inflammatory cytokines in the patients with chronic hepatitis C. Hepatogastroenterology. 2009;56:1704–1709.PubMed
78.
Milazzo L, Meroni L, Galazzi M, et al. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients. J Viral Hepat. 2009;16:479–484.PubMedCrossRef
79.
Bader T, Fazili J, Madhoun M, et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol. 2008;103:1383–1389.PubMedCrossRef
80.
Rao GA, Pandva PK. Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. Gastroenterology. 2011;140:144–152.PubMedCrossRef
81.
Shimada M, Yoshida S, Masuzaki R, Schuppan D. Pitavastatin enhances antiviral efficacy of standard pegylated interferon plus ribavirin in patients with chronic hepatitis C: a prospective randomized pilot study. J Hepatol. 2012;56:298–302.CrossRef
82.
Bader T, Korba B. Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro. Antiviral Res. 2010;86:241–245.PubMedCrossRef
83.
Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol. 2009;43:990–994.PubMedCrossRef
84.
Abraldes JG, Albillos A, Banares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136:1651–1658.PubMedCrossRef
85.
El-Serag HB, Johnson ML, Hachem C, et al. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology. 2009;136:1601–1608.PubMedCrossRef
86.
Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B infection. J Clin Oncol. 2012;30:623–630.
87.
Zhang W, Wu J, Zhou L, Xie HY, Zheng SS. Fluvastatin, a lipophilic statin, induces apoptosis in human hepatocellular carcinoma cells through mitochondria-operated pathway. Indian J Exp Biol. 2010;48:1167–1174.PubMed
88.
Relja B, Meder F, Wilhelm K, Henrich D, Marzi I, Lehnert M. Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 2010;26:735–741.PubMedCrossRef
89.
Relja B, Meder F, Wang M, et al. Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK. Int J Oncol. 2011;38:879–885.
90.
Popovich DG, Tiaras F, Yeo CR, Zhang W. Lovastatin interacts with natural products to influence cultured hepatocarcinoma cell (hep-g2) growth. Am Coll Nutr. 2010;29:204–210.
91.
Dold S, Laschke MW, Lavasani S, et al. Simvastatin protects against cholestasis-induced liver injury. Br J Pharmacol. 2009;156:466–474.PubMedCrossRef
92.
Demirbilek S, Tas E, Gurunluoglu K, et al. Fluvastatin reduced liver injury in rat model of extrahepatic cholestasis. Ped Surg Int. 2007;23:155–162.CrossRef
93.
Russo L, Gracia-Sancho J, García-Calderó H, et al. Addition of simvastatin to cold storage prevents endothelial dysfunction in explanted rat livers. Hepatology. 2012;55:921–930.PubMedCrossRef
94.
Graham DJ, Drinkard CR, Shatin D, et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA. 2001;286:831–833.PubMedCrossRef
95.
Sniderman AD. Is there value in liver function test and creatine phosphokinase monitoring with statin use? Am J Cardiol. 2004;94:30F–34F.PubMedCrossRef
96.
Leaver H. Compliance to recommended liver function monitoring in patients on statin therapy. Cardiovasc Ther. 2009;27:96–100.PubMedCrossRef
97.
McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97:89C–94C.
98.
Ward S. A systemic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11:1–160.
99.
Mac Carthy EP. Important Drug Warning. Market withdrawal of Baycol (cervistatin). Bayer Corporation, West Haven, CT. August 8, 2001.
100.
Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;22:441–457.
101.
Marciante KD, Durda JP, Heckbert SR, et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011;21:280–288.PubMedCrossRef
102.
Conforti A, Magro L, Moretti U, et al. Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy. Drug Saf. 2006;29:1163–1172.PubMedCrossRef
103.
De Valle MB, Av Klinteberg V, Alem N, Olsson R, Bjornsson E. Drug-induced liver injury in Swedish University Hospital Outpatient Hepatology Clinic. Aliment Pharmacol Ther. 2006;24:1187–1195.PubMedCrossRef
Metadaten
Titel
Clinical Perspective: Statins and the Liver—Harmful or Helpful?
verfasst von
James H. Lewis
Publikationsdatum
01.07.2012
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 7/2012
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2207-3

Weitere Artikel der Ausgabe 7/2012

Digestive Diseases and Sciences 7/2012 Zur Ausgabe

Original Article

Nutrition, Intestinal Permeability, and Blood Ethanol Levels Are Altered in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)

Original Article

Neutrophil Infiltration of the Colon Is Independent of the FPR1 yet FPR1 Deficient Mice Show Differential Susceptibilities to Acute Versus Chronic Induced Colitis

Original Article

The Spontaneous Course of Liver Enzymes and Its Correlation in Nonalcoholic Fatty Liver Disease

Original Article

Accuracy of Urea Breath Test Performed Immediately After Emergency Endoscopy in Peptic Ulcer Bleeding

Correspondence

Tracheal Aspiration of Capsule Endoscopes: Detection, Management, and Susceptibility

Original Article

Pancreaticoduodenectomy for the Treatment of Groove Pancreatitis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

10.05.2024 Periphere arterielle Verschlusskrankheit Nachrichten

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise